跳至主要内容

Large Animal Models


Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform that focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs. The platform not only offers standard disease model development services but is also skilled in customizing complex disease models to meet the diverse research needs of clients.  In addition, the platform provides a full range of services from drug screening and efficacy evaluation to safety assessment, helping clients accelerate the new drug development process.

  • With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development. Due to their higher physiological similarity to humans, these models are particularly valuable in the research of cardiovascular diseases, metabolic disorders, inflammatory immune diseases, and neurological diseases.
    In order to assist clients in precisely selecting suitable large animal models, Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform. This platform focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs, and offers comprehensive and in-depth disease model development and pharmacodynamic research.  The platform is equipped with world-class experimental facilities and equipments and is supported by a team of experienced scientists and technical experts. This professional team is dedicated to providing pharmacodynamic research services, including experimental protocal design, model establishment, and data analysis, to accelerate the translation of scientific research results into clinical applications.
Diverse Disease Models, Empowering Drug Development Innovation
  • The Medicilon Large Animal Pharmacodynamic Research Service Platform encompasses a wide range of disease models, including but not limited to metabolic diseases (such as obesity, diabetes, and hyperuricemia), cardiovascular diseases (such as thrombosis, stroke, and atherosclerosis), inflammatory and immune diseases (such as arthritis, osteoporosis, and psoriasis), as well as other disease models. This comprehensive coverage addresses nearly all major disease areas in current drug development.
    Table 1: Types of Large Animal Pharmacodynamic Models Conducted by Medicilon
    Disease AreasLarge Animal Disease Models
    Metabolic Disease ModelsObesity and Diabetes Models
    Hyperuricemia Models
    Liver Fibrosis Models
    Pulmonary Fibrosis Models
    Dyslipidemia Models
    Non-Alcoholic Fatty Liver Models
    Hepatobiliary Models
    Inflammatory and Immune Disease ModelsArthritis and Osteoarthritis Models
    Osteoporosis Models
    Psoriasis Models
    Atopic Dermatitis Models
    Multiple Sclerosis Models
    Acute Inflammation Models
    Cardiovascular Disease ModelsThrombosis and Anticoagulation Models
    Stroke Models
    Atherosclerosis Models
    Anemia Models
    Other Disease ModelsSkin Wound Models
    Kidney Failure and Injury Models
    Gynecological Disease Models
AAALAC Certification, Animal Facilities Meet International Standards
  • Medicilon's preclinical animal testing facility has been accredited by AAALAC International since 2009 and has consistently passed re-evaluations. The facility meets international standards in experimental animal quality, animal welfare, and biosafety.
    Table 2: Current Large Animal Capacity at Medicilon
    SpeciesNumber of RoomsCapacity
    Non-Human Primates612,260
    Dogs621,720
    Rabbits14520
    Miniature Pigs10200
    Medicilon's large animal efficacy research and development service platform currently boasts spacious animal housing. From animal care and management to experimental procedures, every step strictly adheres to international standards, providing a solid foundation for large-scale, high-quality, and efficient efficacy experiments.
Advanced Instruments and Equipment Enhance R&D Efficiency and Effectiveness
  • The platform is equipped with advanced large animal experimental instruments, pharmacodynamic experimental analysis equipment, and pharmacodynamic experimental pathological research devices, providing strong technical support for disease efficacy evaluation and ensuring the accuracy and reliability of the experimental process.
    1. Large Animal Experimental Instruments and Equipment
    Large Animal Experimental Instruments and Equipment.webp
    2. Pharmacodynamic Experimental Analysis Equipment
    Pharmacodynamic Experimental Analysis Equipment.webp
    3. Pharmacodynamic Experimental Pathological Research Equipment
    Pharmacodynamic Experimental Pathological Research Equipment.webp
  • In the ever-evolving wave of the biopharmaceutical field, Medicilon's large animal efficacy research and development service platform adheres to the principles of innovation leadership, openness, and collaborative win-win strategies. The platform continuously deepens the expansion of its functions and service boundaries.  The platform will actively explore new methods and technologies for constructing disease models, continuously enriching and developing models for neurological disorders, inflammatory and immune diseases, cardiovascular and metabolic disorders, digestive system diseases, ocular diseases, and other conditions. This aims to provide clients with more precise, efficient, and comprehensive drug development solutions.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...